Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 in Moderately to Severely Active Ulcerative Colitis
NCT06254950Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Mar 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 2 trial of zasocitinib in ulcerative colitis (UC), sponsored by Takeda. Started Mar 2024; status: active, not recruiting.
02
Drugs
zasocitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06254950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254950.